Innovative Pain Treatments Tremeau specializes in developing non-opioid pain therapies with a focus on COX-2 selective NSAIDs, addressing significant unmet needs in acute and chronic pain management for well-defined patient populations.
Strategic Product Pipeline The company's development of TRM-362, a deuterium-enriched etoricoxib compound for acute pain, presents opportunities to collaborate with healthcare providers and specialists seeking advanced pain relief options.
Growth Through Generics Tremeau's initiative to develop a generic version of Vioxx for severe joint pain in hemophilia patients indicates potential partnerships with hospitals, pain clinics, and pharmaceutical distributors serving niche markets.
Funding and Expansion With over 110 million dollars in funding and recent progress in novel drug development, Tremeau is well-positioned for strategic partnerships with investors and healthcare organizations interested in innovative non-opioid pain solutions.
Targeted Market Positioning Operating in the highly competitive pharmaceutical landscape with a focus on rare disease pain management, Tremeau offers opportunities to collaborate with specialists and healthcare systems prioritizing specialized pain treatments.
$1B$10B
$10B
$1B$10B
$10B
$10B
$10B
$10B
$1B$10BTremeau Pharmaceuticals, Inc. uses 8 technology products and services including QuickBooks, iCIMS, Amazon S3, and more. Explore Tremeau Pharmaceuticals, Inc.'s tech stack below.
| Tremeau Pharmaceuticals, Inc. Email Formats | Percentage |
| First.Last@tremeaurx.com | 85% |
| Last@tremeaurx.com | 10% |
| Fir.Last@tremeaurx.com | 5% |
| First.Last@tremeau.com | 100% |
Pharmaceutical ManufacturingMassachusetts, United States0-1 Employees
Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs. Tremeau’s unique approach to acute and chronic pain in select conditions is rooted in the mechanism of action, documented efficacy, and clinically differentiated profile of COX-2 selective NSAIDs.
Company Overview
Media & News
Funding & FinancialsTremeau Pharmaceuticals, Inc. has raised a total of $110M of funding over 2 rounds. Their latest funding round was raised on Dec 09, 2020 in the amount of $110M.
Tremeau Pharmaceuticals, Inc.'s revenue is estimated to be in the range of $1M$10M
Funding & FinancialsTremeau Pharmaceuticals, Inc. has raised a total of $110M of funding over 2 rounds. Their latest funding round was raised on Dec 09, 2020 in the amount of $110M.
Tremeau Pharmaceuticals, Inc.'s revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com